Skip to main content
SpringerLink
Log in

Baseline FACT-G score is a predictor of survival for advanced lung cancer

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

The objective of this study is to evaluate whether patient-reported baseline health-related quality of life (HRQL) measured by the Functional Assessment of Cancer Therapy-General (FACT-G) instrument is predictive of survival for patients with advanced lung cancer. Methods: Consecutive patients with advanced lung cancer planning to undergo palliative chemotherapy in the outpatient clinics of a Canadian tertiary care cancer centre were enrolled on study. FACT-G total scores and clinical predictors of survival (age, sex, histology, stage of disease, previous weight loss, presence of liver metastases and performance status) were prospectively collected at baseline. Survival data was subsequently collected retrospectively from the Alberta Cancer Registry. Stratified Cox Proportional Hazards analysis was done examining the influence of baseline total FACT-G scores on survival, controlling for potential clinical confounders. Results: Median survival of the 42 patient cohort was 9.9 months with a 2-year survival of 16.7%. Multivariate analysis indicated that baseline FACT-G total score is significantly associated with survival (p= 0.004). Conclusion: Baseline HRQL is a statistically significant predictor of survival for patients with advanced lung cancer. When used along with traditional clinical factors, patient-reported baseline HRQL assessment using the FACT-G provides additional prognostic information to the patient and clinician.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dancey J, Zee B, Osoba D, et al. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 1997; 6(2): 151–158.

    Google Scholar 

  2. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trials. Chest 1994; 106(6 Suppl): 324S–328S.

    PubMed  Google Scholar 

  3. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993;29A(12): 1731–1734.

    Article  PubMed  Google Scholar 

  4. Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59(2): 231–242.

    Article  PubMed  Google Scholar 

  5. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 1992; 10(12): 1833–1838.

    Google Scholar 

  6. Coates A, Forbes J, Simes RJ. Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 1993; 11(10): 2050.

    Google Scholar 

  7. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer1991; 67(12): 3131–3135.

    Google Scholar 

  8. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumour size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1996; 14(1): 171–175.

    PubMed  Google Scholar 

  9. NCIC. Canadian Cancer Statistics 2001. Toronto: Canadian Cancer Society. National Cancer Institute of Canada, 2001.

    Google Scholar 

  10. Cagle P. Pathology of the Lung. In: Thurlbeck W (ed.), Tumours of the Lung.New York: Thieme Medical Publishers, 1995; 437–551.

  11. Cella D. FACIT Manual: Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System (version 4): Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1993 (November 1997).

  12. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11 (3): 570–579.

    Google Scholar 

  13. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG Performance Status Scoring in Lung Cancer: A Prospective Longitudinal Study of 536 Patients From a Single Institution. Eur J Cancer 1996; 32A(7): 1135–1141.

    Article  PubMed  Google Scholar 

  14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649–655.

    PubMed  Google Scholar 

  15. Mulshine JL, Makuch RW, Johnston-Early A, et al. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol 1984; 2(7): 733–741.

    PubMed  Google Scholar 

  16. Naughton MJ, Herndon JE II, Shumaker SA, et al. The health-related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033. Qual Life Res 2002; 11(3): 235–248.

    Article  PubMed  Google Scholar 

  17. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991; 99(6): 1425–1432.

    Google Scholar 

  18. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: Tables and comments. Eur Respir J 1994; 7(7): 1350–1364.

    Article  PubMed  Google Scholar 

  19. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base report on lung cancer. Cancer 1996; 77(9): 1947–1955.

    Article  PubMed  Google Scholar 

  20. Prasad US, Naylor AR, Walker WS, Lamb D, Cameron EW, Walbaum PR. Long term survival after pulmonary resection for small cell carcinoma of the lung. Thorax 1989; 44(10): 784–787.

    PubMed  Google Scholar 

  21. Ginsberg R, Vokes E, Rosenzweig K. Non-Small Cell Lung Cancer. In: DeVita V, Hellman S, Rosenberg S (eds), 1215 Cancer: Principles and Practice. Philadelphia, PA: Lippencott Williams & Wilkins, 2001: 925–982.

    Google Scholar 

  22. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer1992; 70(5): 1102–1110.

    Google Scholar 

  23. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years-an analysis of 1714 consecutive patients. J Clin Oncol1995; 13(5): 1215–1220.

    PubMed  Google Scholar 

  24. AJCC. Lung. In: AJCC Cancer Staging Manual, 5th ed. Philidelphia: Lippencott-Raven Publishers; 1997.

    Google Scholar 

  25. Microsoft Excel 97 SR-2. Q985-1997 Microsoft Corporation.

  26. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 1992; 28A(8-9): 1328–1330.

    Article  PubMed  Google Scholar 

  27. Curran D, Fayers P, Molenberghs G, Machin D. Analysis of incomplete quality of life data in clinical trials. In: Saquet M, Hayes R, Fayers P (eds), Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press, 1998: 250–280.

    Google Scholar 

  28. SAS. SAS Institute, Cary, NC, USA.

  29. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88(6): 1294–1303.

    Article  PubMed  Google Scholar 

  30. Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum 1999; 26(5): 921–925.

    PubMed  Google Scholar 

  31. Langendijk JA, Aaronson NK, ten Velde GP, de Jong JM, Muller MJ, Wouters EF. Pretreatment quality of life of inoperable non-small cell lung cancer patients referred for primary radiotherapy. Acta Oncol 2000; 39(8): 949–958.

    Article  PubMed  Google Scholar 

  32. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 2000; 55(1): 19–25.

    Article  PubMed  Google Scholar 

  33. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol1989; 15: 235–242.

    Google Scholar 

  34. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: As an important prognostic factor. Lung Cancer 2001; 31(2-3): 233–240.

    Article  PubMed  Google Scholar 

  35. Herndon JE II, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 1999; 85(2): 333–340.

    Article  PubMed  Google Scholar 

  36. Cella D. Impact of ZD1839 on Non-Small Cell Lung Cancer-Related Symptoms as Measured by the Functional Assessment of Cancer Therapy-Lung Scale. Sem Oncol 2003; 30 (Suppl 1): 39–48.

    Article  Google Scholar 

  37. Moinpour CM, Lyons B, Grevstad, PK, et al. Quality of life in advanced non-small cell lung cancer: Results of a Southwest Oncology Group randomized trial. Qual Life Res 2002; 11: 115–126.

    Article  PubMed  Google Scholar 

  38. Bonomi P, Gale M, Rowland K, et al. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys 1991; 20(2): 247–252.

    PubMed  Google Scholar 

  39. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990; 61(4): 597–604.

    Google Scholar 

  40. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987; 39(2): 146–149.

    PubMed  Google Scholar 

  41. Cella DF, Cherin EA. Quality of life during and after cancer treatment. Compr Ther 1988; 14(5): 69–75.

    Google Scholar 

  42. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994; 12(3): 608–616.

    PubMed  Google Scholar 

  43. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 1984; 2(5): 472–483.

    PubMed  Google Scholar 

  44. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365–376.

    PubMed  Google Scholar 

  45. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, Crowley J.Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 1989; 81(7): 485–495.

    PubMed  Google Scholar 

  46. Presant CA.Quality of life in cancer patients. Who measures what?Am J Clin Oncol 1984; 7(5): 571–573.

    Google Scholar 

  47. Del Guerico L, Crohn J. Monitoring Operative Risk in the Elderly. J Am Med Assoc 1983; 240: 1350–1350.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Graduate Studies and Research, University of Alberta, Edmonton, AB, Canada

    M. Dharma-Wardene & M. Dharma-Wardene

  2. Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

    M. Dharma-Wardene, H.-J. Au, J. Hanson & J. Hewitt

  3. Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

    H.-J. Au

  4. Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

    D. Dupere

  5. Institute of Health Economics, University of Alberta, Edmonton, AB, Canada

    D. Feeny

  6. Faculty of Pharmacy and Pharmaceutical Sciences and Department of Public Health Sciences, University of Alberta, Edmonton, AB, Canada

    D. Feeny

  7. Dundas, ON, Canada

    D. Feeny

Authors
  1. M. Dharma-Wardene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.-J. Au
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Dupere
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Hewitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Feeny
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dharma-Wardene, M., Au, HJ., Hanson, J. et al. Baseline FACT-G score is a predictor of survival for advanced lung cancer. Qual Life Res 13, 1209–1216 (2004). https://doi.org/10.1023/B:QURE.0000037481.36604.eb

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:QURE.0000037481.36604.eb

Search

Navigation